Misyo (Methadone Hydrochloride)

Methadone hydrochloride is a full agonist at the mu‑opioid receptor. By binding to this receptor, it activates the same pathways as other opioids, producing analgesia and suppressing the neurochemical signals that cause withdrawal, while its long half‑life maintains steady receptor occupancy.

The appropriate dose of Misyo is individualized by the prescribing clinician based on factors such as the patient’s opioid tolerance, treatment goals, liver function, and response to therapy. Dosage adjustments are made during initiation and maintenance phases to achieve optimal control of withdrawal or pain.

Safety data for methadone hydrochloride in pregnancy and lactation are limited. It may be used when the benefits outweigh potential risks, but clinicians should assess each case carefully and monitor both mother and infant for adverse effects. Breastfeeding decisions should follow local guidelines and professional advice.

To order Misyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both methadone (Misyo) and buprenorphine are used for opioid dependence, but methadone is a full mu‑opioid agonist offering stronger analgesia and a longer half‑life, while buprenorphine is a partial agonist with a ceiling effect on respiratory depression. Choice depends on patient history, treatment setting, and risk‑benefit considerations.

Misyo should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in areas with high humidity or extreme temperatures.

Misyo is administered orally, typically as a tablet or solution taken by mouth. The exact route (tablet or liquid) and dosing schedule are determined by the prescriber, who will provide instructions on how and when to take the medication for optimal effect.

The most serious risks include respiratory depression, which can be life‑threatening, especially when combined with other CNS depressants, and cardiac arrhythmias related to QT interval prolongation. Patients should be monitored closely during initiation and dose adjustments to mitigate these hazards.

Misyo is contraindicated in individuals with acute respiratory depression, severe asthma, known hypersensitivity to methadone, or uncontrolled cardiac arrhythmias. Caution is also advised for patients with significant hepatic impairment, as dose reductions may be required.